Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

Vaccinations

Vaccinations

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Cross-reactivity

Cross-reactivity

Smallpox

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The impact of reinsurance of gene therapies on employer financial risk.

The American journal of managed care·2021

Same author

PATIENT WEB PORTALS AND PATIENT-PROVIDER RELATIONSHIPS: A SUMMARY PERSPECTIVE.

International journal of technology assessment in health care·2017

Same author

ADHD in managed care: an assessment of the burden of illness and proposed initiatives to improve outcomes.

The American journal of managed care·2009

Same author

Colorectal cancer: complexities and challenges in managed care.

Journal of managed care pharmacy : JMCP·2007

Same author

Medication reconciliation: Harvard Pilgrim Health Care's approach to improving outpatient medication safety.

Journal for healthcare quality : official publication of the National Association for Healthcare Quality·2007

Same author

The role of guidelines in managing diseases.

Managed care (Langhorne, Pa.)·2006

Search research articles

Related Experiment Video

Updated: Jul 10, 2026

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

Multiple vaccines: how do we choose?

Neil B Minkoff¹

¹Harvard Pilgrim Health Care, MA 02481, USA. neil_minkoff@harvardpilgrim.org

Journal of Managed Care Pharmacy : JMCP

|October 25, 2007

Summary

Managed care organizations (MCOs) need to re-evaluate vaccine coverage policies due to emerging vaccines. Utilizing Pharmacy & Therapeutics (P&T) committees and considering safety, efficacy, and value ensures optimal decision-making for new vaccine products.

Area of Science:

Health policy
Preventive medicine
Pharmaceutical management

Background:

Preventive medicine is crucial in managed care, with traditional automatic vaccine coverage via the medical benefit.
Emerging vaccines necessitate revised decision-making processes for managed care stakeholders.
Multiple products targeting the same disease require careful product selection.

Purpose of the Study:

Review traditional vaccine coverage drivers in managed care.
Discuss the need for managed care organizations (MCOs) to critically examine vaccine policies.
Address the evolving landscape of emerging vaccines.

Main Methods:

Evaluation of vaccine policies within managed care organizations (MCOs).
Utilizing Pharmacy & Therapeutics (P&T) committees and technology assessment committees for review.

More Related Videos

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Published on: May 19, 2023

Related Experiment Videos

Last Updated: Jul 10, 2026

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Published on: May 19, 2023

Application of criteria including safety, efficacy, cost, and value.

Main Results:

Variable vaccine coverage is a novel concept in managed care.
Pharmacy & Therapeutics (P&T) committees are effective for vaccine evaluation.
Technology assessment committees may be more appropriate in certain cases.
Standard pharmaceutical review criteria apply to vaccines.

Conclusions:

MCOs must enhance examination of vaccine policies due to novel agents.
P&T and technology assessment committees are key evaluation avenues.
Criteria include safety, efficacy, cost-effectiveness, and vaccine-specific factors.